查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1931244

植入式药物释放球囊市场：按适应症、产品类型、药物类型、最终用户分類的全球预测（2026-2032年）

Implantable Drug Eluting Balloon Market by Indication, Product Type, Drug Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，植入式药物释放型球囊市场价值将达到 12.5 亿美元，到 2026 年将成长至 13.4 亿美元，到 2032 年将达到 21.3 亿美元，复合年增长率为 7.86%。

关键市场统计数据
基准年 2025 12.5亿美元
预计年份：2026年 13.4亿美元
预测年份 2032 21.3亿美元
复合年增长率 (%) 7.86%

全面介绍植入式药物释放型球囊领域，重点在于临床证据、技术成熟度和不断变化的相关人员优先事项。

生物相容性药物释放型球囊技术处于介入治疗创新与不断变化的临床需求的交汇点，它提供了一种结合机械扩张和局部药物控制内膜增生的递送平台。近年来，临床医生对永久性支架的替代方案越来越感兴趣，尤其是在维持血管顺应性和最大限度减少异物负荷是临床首要考虑因素的情况下。随着技术的成熟，临床、监管和商业相关人员正在重新评估药物释放型球囊与药物释放型支架和新兴生物可吸收技术相比的作用。

临床个人化、技术进步与监管如何融合，重新定义药物释放型球囊商业化的策略路径

随着临床实务、装置技术和监管要求的同步发展，植入式药物释放型球囊的格局正在改变性变化。临床治疗正朝着个人化血管治疗方向显着转变，介入医师会根据病变形态、病患合併症和长期血管保护策略来优化器械选择。这一趋势有利于那些能够最大限度减少长期植入负担并保留未来治疗选择的技术，从而提升了药物释放型球囊平台的战略重要性。

本文分析了2025年关税将如何重塑整个设备价值链的采购、製造在地化和采购策略。

2025年实施的关税和贸易措施显着增加了支持植入式药物释放型球囊的全球供应链的复杂性，影响了供应商的选择、製造地和筹资策略。关税带来的成本压力迫使製造商重新评估其采购来源，尽可能优先考虑近岸外包和本地生产，以降低跨境关税风险并缩短前置作业时间。这种转变不仅影响最终设备的组装，也影响关键零件的采购，例如特殊聚合物、药物涂层製剂和精密导管组件。

关键細項分析将临床适应症、器材类型、药理学和临床环境与策略发展和商业化选择连结起来。

基于细分市场的洞察揭示了临床应用案例、产品设计、药物以及医疗环境如何共同影响药物释放型球囊的开发和商业化策略。根据适应症，市场可分为新兴病变和支架内再血管再阻塞，其中新发病变可细分为冠状动脉疾病和周边动脉疾病。冠状动脉疾病进一步分为急性病变和慢性完全闭塞，而周边动脉疾病则分为膝下和股腘动脉区域。这些临床差异导致了不同的设计重点：冠状动脉应用需要超低轮廓、高顺应性的导管，以便在復杂的血管解剖结构中进行短时扩张；而外周动脉应用则倾向于优先考虑更长的球囊长度、更高的标称压力和更强的药物滞留能力，以适应不同的血管壁生物学特性。

区域趋势和差异化的准入策略将影响全球医疗保健生态系统的采纳路径和商业化重点。

区域趋势对植入式药物释放型球囊的临床应用、监管路径和商业性需求有显着影响。在美洲，介入性心臟病学基础设施的投资、完善的导管介入手术报销机制以及冠状动脉介入治疗的高普及率，共同营造了一种环境，使得冠状动脉应用成为优先考虑的领域，支付方和综合医疗网络对临床证据进行严格审查。该地区日益重视进行严谨的随机对照试验和真实世界证据研究，以证明其具有可比较的临床疗效和成本效益，从而支持更广泛的应用。

策略竞争动态揭示了技术差异化、临床证据和供应链韧性如何塑造药物释放型球囊领域的领导地位。

药物释放型球囊领域的竞争主要集中在技术差异化、临床证据产生和供应链韧性。领先的研发企业正致力于改进载体化学和涂层均匀性，以优化短时间内药物的输送，同时也投资于导管输送性和触觉回馈，这对于复杂病变至关重要。随着医疗设备製造商权衡自身能力与外包精密涂层和包装技术之间的利弊，他们与专业契约製造之间的合作也日益普遍。

透过整合临床疗效检验、供应链多元化和市场进入策略优化等切实可行的建议，加速永续应用并提升竞争优势。

为了加速药物释放型球囊的持续应用，产业领导者应采取整合策略，同时兼顾临床验证、供应链灵活性和客製化市场进入。优先开展以支付方和临床医生需求为导向的临床项目，将创造更具吸引力的价值提案。将终点指标与卫生经济学相结合的实用性试验和真实世界证据项目，可以缩短从监管部门核准到常规应用的路径。同时，企业应考虑生产多元化和区域生产伙伴关係，以降低关税风险并更好地应对力在地采购趋势。

我们采用透明、多方面的调查方法，结合与临床医生面对面的交谈、观察他们的工作以及严格的二次分析，以支持策略决策。

本研究整合了一手和二手资料，对药物释放型球囊疗法进行了全面且可重复的评估。一级资讯来源包括对介入医师、采购人员、监管专家和生产合作伙伴的结构化访谈，以及对临床环境中手术流程和设备操作的观察分析。这些直接访谈旨在了解影响该疗法应用的临床决策因素和操作限制，同时检验关于设备在真实环境中表现的陈述。

在他的策略概述中，他强调，整合临床、营运和商业合作对于实现药物释放型球囊的长期价值至关重要。

总之，植入式药物释放型球囊领域正进入一个关键阶段，技术成熟度、临床差异化以及策略性供应选择将决定最终的竞争者。该设备的核心提案在于无需永久植入即可提供局部抗增殖治疗，这与临床医生对血管保护和灵活治疗方案的需求不谋而合。然而，要充分发挥这一提案，需要对临床证据、设备性能以及能够适应不同医疗环境和区域市场动态的商业模式进行持续投入。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依适应症分類的植入式药物输送球囊市场

  • 新病变
    • 冠状动脉疾病
    • 周边动脉疾病
  • 支架内血管再阻塞

第九章 依产品类型植入式药物释放球囊市场

  • 冠状动脉
  • 週边血管

第十章 依药物类型植入式药物喷射球囊市场

  • 紫杉醇
  • Sirolimus

第十一章 以最终用户分類的植入式药物释放球囊市场

  • 门诊手术中心
  • 心臟中心
  • 医院
    • 私立医院
    • 公立医院

第十二章 区域性植入式药物释放球囊市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章植入式药物释放球囊市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国植入式药物释放球囊市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国植入式药物喷射球囊市场

第十六章：中国植入式药物喷射球囊市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • Alvimedica Medical Technologies Inc.
  • AngioDynamics, Inc.
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Concept Medical, Inc.
  • ConMed Corporation
  • Cook Medical Incorporated
  • Eurocor GmbH
  • iVascular SLU
  • Koninklijke Philips NV
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medtronic plc
  • MicroPort Scientific Corporation
  • Opto Circuits（India）Ltd.
  • Paladin Medical Pvt. Ltd.
  • Terumo Corporation
Product Code: MRR-7B550E008DE0

The Implantable Drug Eluting Balloon Market was valued at USD 1.25 billion in 2025 and is projected to grow to USD 1.34 billion in 2026, with a CAGR of 7.86%, reaching USD 2.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.25 billion
Estimated Year [2026] USD 1.34 billion
Forecast Year [2032] USD 2.13 billion
CAGR (%) 7.86%

A comprehensive introduction to the implantable drug eluting balloon field highlighting clinical rationale, technological maturation, and evolving stakeholder priorities

The implantable drug eluting balloon sector sits at the intersection of interventional innovation and evolving clinical needs, offering a delivery platform that combines mechanical dilation with localized pharmacologic inhibition of neointimal proliferation. Recent years have seen growing interest from clinicians seeking alternatives to permanent stents, particularly where preserving vessel compliance and minimizing foreign-body burden are clinical priorities. As the technology matures, stakeholders across clinical, regulatory, and commercial domains are reassessing the role of drug eluting balloons relative to drug-eluting stents and emerging bioresorbable technologies.

Advances in drug formulations, excipient chemistry, and balloon coating techniques have improved drug transfer efficiency during brief inflation windows, while iterative improvements in catheter design have enhanced deliverability in complex anatomies. Clinicians are increasingly differentiating indications by lesion context, such as de novo disease versus in-stent restenosis, and across coronary and peripheral vascular territories. These clinical nuances are shaping both trial design and real-world adoption patterns. Consequently, strategic priorities for manufacturers now extend beyond engineering and clinical validation to encompass supply chain resilience, regulatory engagement, and nuanced payer communications that reflect the distinct value proposition of local drug delivery without permanent implants.

How clinical personalization, technological advances, and regulatory scrutiny are converging to redefine strategic pathways for drug eluting balloon commercialization

Transformative shifts are reshaping the landscape for implantable drug eluting balloons as clinical practice, device technology, and regulatory expectations co-evolve. There is a clear clinical shift toward personalized vascular care, with interventionalists tailoring device selection to lesion morphology, patient comorbidity, and long-term vessel preservation strategies. This trend favors technologies that minimize chronic implant burden and preserve future treatment options, elevating the strategic relevance of drug eluting balloon platforms.

On the technology front, improvements in drug carrier matrices and transfer kinetics are enabling more predictable tissue uptake during short balloon inflation periods, which in turn supports broader use across complex coronary lesions and challenging peripheral anatomies. Concurrently, payer and regulatory scrutiny of clinical endpoints is intensifying, pushing manufacturers to design robust comparative studies that demonstrate meaningful patient-centric benefits such as reduced reintervention rates, improved limb salvage outcomes in peripheral disease, or decreased incidence of late adverse events. The convergence of these forces is prompting manufacturers to adopt integrated development approaches that couple engineering innovation with targeted clinical programs and commercial models that address differentiated end-user needs.

An analytical examination of how 2025 tariff measures are reshaping sourcing, manufacturing localization, and procurement strategies across the device value chain

The imposition of tariffs and trade measures in 2025 has introduced a material layer of complexity for global supply chains supporting implantable drug eluting balloons, influencing sourcing choices, manufacturing footprints, and procurement strategies. Tariff-driven cost pressures have incentivized manufacturers to reassess input sourcing, favoring nearshoring or regional production where feasible to reduce exposure to cross-border duties and to shorten lead times. This reorientation affects not only final device assembly but also the sourcing of critical components such as specialized polymers, coated drug formulations, and precision catheter subassemblies.

Procurement teams within hospital systems and ambulatory centers are reacting by revisiting supplier qualification criteria and total landed cost models rather than relying solely on unit price. In turn, contract negotiations increasingly emphasize supply continuity guarantees, inventory buffers, and collaborative risk-sharing arrangements that mitigate the commercial impact of sudden duty changes. Regulatory interactions have also been influenced, as manufacturers balance the need to maintain consistent device specifications across markets with the operational realities of diversified manufacturing. Ultimately, the cumulative impact of tariffs has accelerated strategic decisions around localization, vertical integration of critical inputs, and contractual mechanisms that stabilize access while preserving clinical quality and device performance.

Key segmentation insights connecting clinical indications, device types, pharmacology, and care settings to strategic development and commercialization choices

Segmentation-driven insights reveal how clinical use cases, product designs, pharmacologic agents, and care settings collectively shape development and commercial strategies for drug eluting balloons. Based on indication, the market divides into de novo lesion and in-stent restenosis, with de novo lesion further differentiated into coronary artery disease and peripheral artery disease. Coronary artery disease is further characterized by acute lesions and chronic total occlusions, while peripheral artery disease splits into below-the-knee and femoropopliteal territories. These clinical distinctions create divergent design priorities: coronary applications demand ultra-low profile, high-trackability catheters calibrated for short inflation times in tortuous anatomy, whereas peripheral use often prioritizes longer balloon lengths, higher nominal pressures, and enhanced drug retention to address different vessel wall biology.

Based on product type, commercial strategies distinguish coronary and peripheral offerings, necessitating separate regulatory evidence packages and sales training models for interventional cardiology versus vascular surgery and interventional radiology audiences. Based on drug type, the choice between paclitaxel and sirolimus influences both clinical positioning and formulation science; paclitaxel's lipophilicity supports rapid tissue uptake while sirolimus and its analogues require advanced carrier systems to achieve effective local delivery, prompting divergent R&D paths. Based on end user, adoption dynamics vary across ambulatory surgical centers, cardiac centers, and hospitals, with hospitals further segmented into private and public institutions; reimbursement pathways, purchasing cycles, and capital allocation norms differ across these settings, shaping go-to-market tactics and education investments. Collectively, these segmentation axes inform trial design, messaging, and supply models that must be aligned to clinical workflows and stakeholder incentives.

Regional dynamics and differentiated access strategies that determine adoption pathways and commercialization priorities across global healthcare ecosystems

Regional dynamics exert a pronounced influence on clinical adoption, regulatory pathways, and commercial imperatives for implantable drug eluting balloons. In the Americas, investment in interventional cardiology infrastructure, established reimbursement frameworks for catheter-based therapies, and a high prevalence of coronary interventions create an environment where coronary applications are prioritized and clinical evidence is closely scrutinized by payers and integrated delivery networks. This region tends to emphasize robust randomized and real-world evidence demonstrating comparative clinical outcomes and cost-effectiveness to support broader uptake.

Across Europe, Middle East & Africa, heterogeneity in regulatory regimes and reimbursement mechanisms requires flexible market-access approaches. Some European markets reward technologies that demonstrate health-economic value and downstream reductions in reintervention, while other jurisdictions adopt more cautious adoption curves driven by national procurement processes. In emerging Middle Eastern and African contexts, infrastructural constraints and differing procedural volumes shape demand toward devices that are cost-effective and operationally resilient. In the Asia-Pacific region, diverse healthcare ecosystems span advanced public-private hospital networks to rapidly growing ambulatory centers; cost sensitivity and volume-driven procurement can favor locally adapted manufacturing strategies, and clinical adoption is accelerated where regulatory pathways support expedited evaluation of devices with clear clinical differentiation. These regional contrasts underscore the need for tailored regulatory, clinical, and commercial roadmaps rather than one-size-fits-all launch strategies.

Strategic competitive dynamics reveal how technological differentiation, clinical evidence, and supply resilience shape leadership in the drug eluting balloon domain

Competitive activity in the drug eluting balloon arena centers on technological differentiation, clinical evidence generation, and supply chain resilience. Leading developers pursue incremental improvements in carrier chemistries and coating uniformity to optimize drug transfer during short inflation windows, while also investing in catheter deliverability and tactile feedback that matters in complex lesions. Partnerships between device manufacturers and specialty contract manufacturers have become common as firms deliberate the trade-offs between in-house capabilities and outsourced expertise for precision coating and packaging.

Clinical trial strategies are a critical axis of competition; companies that design head-to-head or pragmatic comparative studies tailored to payer-relevant endpoints can more effectively articulate value propositions. Strategic monetization approaches vary by firm, with some prioritizing direct hospital relationships and capital sales, while others pursue distributor networks and bundled service offerings that include training, procedural support, and outcomes tracking. Collaboration with key clinical opinion leaders and investment in post-market registries further differentiate players by demonstrating long-term performance across both coronary and peripheral indications. Finally, robustness of quality systems and regulatory alignment across jurisdictions is increasingly decisive, as purchasers place a premium on suppliers that can reliably deliver devices under shifting trade and regulatory conditions.

Actionable recommendations that integrate clinical validation, supply chain diversification, and tailored market access to accelerate durable adoption and competitive advantage

Industry leaders should adopt an integrated strategy that simultaneously addresses clinical proof, supply chain agility, and tailored market access to accelerate sustainable adoption of drug eluting balloons. Prioritizing clinical programs that are designed with payers and clinicians in mind will yield more compelling value narratives; pragmatic trials and real-world evidence initiatives that align endpoints with health-economic relevance can shorten the pathway from regulatory clearance to routine use. At the same time, companies should evaluate manufacturing diversification and regional production partnerships to mitigate tariff exposure and to improve responsiveness to local procurement preferences.

Commercial organizations must invest in differentiated engagement models for coronary and peripheral stakeholders and adapt training and reimbursement support to the specific needs of ambulatory centers, cardiac centers, and both public and private hospitals. Technology roadmaps should emphasize modular innovations that support both paclitaxel and sirolimus-based platforms, enabling portfolio flexibility as clinical preferences evolve. Finally, establishing collaborative procurement frameworks with large health systems and aligning warranty or outcomes-based contracting can create stronger commercial anchors, reduce adoption risk for customers, and enhance long-term uptake across multiple geographies.

A transparent, multi-method research methodology combining primary clinician engagement, operational observation, and rigorous secondary analysis to inform strategic decisions

This research synthesizes primary and secondary intelligence to produce a comprehensive, replicable assessment of the implantable drug eluting balloon landscape. Primary inputs include structured interviews with interventional clinicians, procurement leaders, regulatory specialists, and manufacturing partners, complemented by observational analysis of procedural workflows and device handling in clinical settings. These direct engagements were designed to capture both clinical decision drivers and operational constraints that influence adoption, as well as to validate real-world device performance narratives.

Secondary research involved systematic review of peer-reviewed clinical literature, regulatory guidance documents, and publicly available technical disclosures related to coatings, drug formulations, and catheter systems. Analytical methods included cross-case synthesis to identify common themes across indications and geographies, scenario analysis to assess the operational impact of trade measures and supply disruptions, and triangulation of qualitative insights with technical literature to ensure consistency. Data integrity measures included cross-validation with multiple expert sources and sensitivity checks on strategic conclusions. The research approach emphasizes transparency, methodological rigor, and practical relevance to support decision-making by clinical leaders, product strategists, and procurement executives.

A strategic concluding synthesis emphasizing the need for integrated clinical, operational, and commercial alignment to realize long-term value in drug eluting balloons

In conclusion, the implantable drug eluting balloon sector is entering a phase where technological refinement, clinical differentiation, and strategic supply choices will determine which players scale successfully. The device's core value proposition-delivering localized antiproliferative therapy without leaving a permanent implant-resonates with clinicians seeking vessel preservation and flexible treatment pathways. However, capitalizing on this proposition requires coordinated investments in clinical evidence, device performance, and commercial models adapted to diverse care settings and regional market dynamics.

As geopolitical and trade dynamics alter the economics of global supply chains, manufacturers that proactively address manufacturing localization, contractual resilience, and end-user education will be better positioned to sustain adoption momentum. The companies that successfully combine rigorous clinical validation with operational agility and payer-focused messaging will create the strongest platform for long-term competitive advantage. Stakeholders should therefore pursue an integrated approach that aligns R&D priorities, regulatory strategy, and commercial execution to realize the full clinical and economic potential of drug eluting balloon technology.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Drug Eluting Balloon Market, by Indication

  • 8.1. De Novo Lesion
    • 8.1.1. Coronary Artery Disease
    • 8.1.2. Peripheral Artery Disease
  • 8.2. In-Stent Restenosis

9. Implantable Drug Eluting Balloon Market, by Product Type

  • 9.1. Coronary
  • 9.2. Peripheral

10. Implantable Drug Eluting Balloon Market, by Drug Type

  • 10.1. Paclitaxel
  • 10.2. Sirolimus

11. Implantable Drug Eluting Balloon Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Cardiac Centers
  • 11.3. Hospitals
    • 11.3.1. Private Hospitals
    • 11.3.2. Public Hospitals

12. Implantable Drug Eluting Balloon Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Implantable Drug Eluting Balloon Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Implantable Drug Eluting Balloon Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Implantable Drug Eluting Balloon Market

16. China Implantable Drug Eluting Balloon Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. Alvimedica Medical Technologies Inc.
  • 17.7. AngioDynamics, Inc.
  • 17.8. B. Braun Melsungen AG
  • 17.9. Becton, Dickinson and Company
  • 17.10. BIOTRONIK SE & Co. KG
  • 17.11. Boston Scientific Corporation
  • 17.12. Cardionovum GmbH
  • 17.13. Concept Medical, Inc.
  • 17.14. ConMed Corporation
  • 17.15. Cook Medical Incorporated
  • 17.16. Eurocor GmbH
  • 17.17. iVascular S.L.U.
  • 17.18. Koninklijke Philips N.V.
  • 17.19. Lepu Medical Technology (Beijing) Co., Ltd.
  • 17.20. Medtronic plc
  • 17.21. MicroPort Scientific Corporation
  • 17.22. Opto Circuits (India) Ltd.
  • 17.23. Paladin Medical Pvt. Ltd.
  • 17.24. Terumo Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL ARTERY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY IN-STENT RESTENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CORONARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PACLITAXEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY SIROLIMUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 112. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 115. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. GCC IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 133. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 136. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. G7 IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 140. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 143. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. NATO IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DE NOVO LESION, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA IMPLANTABLE DRUG ELUTING BALLOON MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)